Transforming ionic liquids into healthcare solutions
CAGE Bio Inc., currently a resident company at Johnson & Johnson Innovation, JLABS @ MBC BioLabs, is a clinical-stage startup exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for dermatology, inflammation, and immunology.
We believe that systemic exposure to drugs should be an exception. Our mission is to develop highly
effective products for localized treatment thereby minimizing side effects from systemic exposure.
Deep eutectic ionic liquids exhibit broad-spectrum antimicrobial action in addition to exceptional solvation and permeation enhancement. Deep eutectic ionic liquids have shown the ability to deliver proteins (eg insulin) and charged macromolecules (eg siRNA) across the stratum corneum.
20+ years in drug development through approvals in the US and EU. Held senior positions at Elan, Alkermes, ALZA (J&J). Co-Founder, Incline Therapeutics acquired by The Medicines Company.
30+ years experience in pharma and med tech operations. Held senior positions at Knoll/BASF Pharma, Abbott Laboratories, and BoneCare Int’l. (acquired by Genzyme). Co-Founder and former CEO of Zurex Pharma.
20+ years’ experience building iconic brands including Campbell Soup, Advil analgesics, & Vaseline skin care at blue-chip marketing organizations (P&G, Unilever, Campbell Soup, Pfizer).
CAGE Bio, TAGCyx, and PeptiStar Announce Execution of a License Agreement for Development and Commercialization of TAGX-0003 for the Treatment of Immunodermatology Diseases Mediated by the IFN-Gamma Pathway